ESTRO 36 Abstract Book

645 / 1082

S629 ESTRO 36 2017
_______________________________________________________________________________________________
RT indications and targets were based on tumors
characteristics pre-NCT. More advanced disease at the
time of diagnosis and age were the main determinants to
define RT to nodal targets independently of NCT response.
EP-1167 Accelerated Partial Breast Irradiation: A
single center analysis.
K. Nugent1, D. Kelly2, J. McCaffrey3, M. Maher4
1 St Lukes Radiation Network, Radiation Oncology,
Dublin, Ireland
2 Cork University Hospital, Medical Oncology, Cork,
Ireland
3 Mater Misericordiae University Hospital, Medical
Oncology, Dublin 6, Ireland
4 Mater Misericordiae University Hospital, Radiation
Oncology, Dublin 6, Ireland
Purpose or Objective
Our objective was to analyse the use of adjuvant
accelerated partial breast radiation (APBI) at our center
over a ten year period. We calculated the local recurrence
rates, median follow up and overall survival in breast
cancer patients who received APBI from 2006 to 2016 . In
this retrospective cohort, we obtained the
average tumour size, histology grade, hormone status and
lymphovascular invasion (LVI) presence in order to review
the breast cancer characteristics of the patients we
selected to treat with this modality.
Material and Methods
We conducted a single institution retrospective review of
all adjuvant breast cancer patients who received APBI
from between January 2006 to September 2016 . Patients
were identified from a prospectively-maintained dataset
of all patients commencing ABPI. A retrospective chart
review was conducted as to determine long term follow up
outcomes. The following patient details were recorded:
median follow up time, demographics, histology, node
status, surgery type, adjuvant treatment and local
recurrence. Primary outcome was loco-regional
recurrence noting if recurrences occurred within the
treated breast quadrant.
Results
During this period a total of 106 procedures were carried
out. The average mean age at time of treatment was 68.2
years. The mean tumour size was 14.65mm, all were
estrogen receptor positive and node negative. LVI was
present in 8% of the patient cohort. Median follow up was
65 months. The local recurrence rate within the treated
breast quadrant was 1.8% (95 CI 0.42-2.44) while the local
recurrence rate within the ipsilateral breast was 2.8% (95
CI 1.2-3.3). Overall survival was 97%.
Conclusion
Our findings suggest that APBI is a reasonable adjuavant
option for selected low risk breast cancer patients.
EP-1168 male breast cancer; a review of patients
treated from 2004 - 2013 (10yrs)
P. Scott 1, V. Vanderpuye1, J. Yarney1, N. Aryeetey1, H.
Ayettey1, M. Dadzie1 , Z. Meles1
1 Korlebu Teaching Hospital, National Centre for
radiotherapy and Nuclear Medicine, ACCRA, Ghana
Purpose or Objective
Male breast carcinoma (MBC) is rare, and the incidence
varies worldwide. It accounts for about 1% of all breast
cancers.
Due to the rarity of this disease, there is a lack of
prospective clinical trials to define its optimum
treatment. Current data consists mostly of small
retrospective studies, hence treatment generally follows
the principles established for that of female breast
cancer.
The purpose of this study was to review and analyse breast
cancer in men managed from 2004 to 2013.
Material and Methods
Men with histologically confirmed breast cancer from
2004–2013 were studied. Information regarding patient
demographics, presenting symptoms, tumor
characteristics, treatment and outcomes were analysed.
Results
Over the 10 year period, 41 patients were studied, making
1.6% of all breast cancer cases managed. Median age at
diagnosis was 66 years, ranging 36-89.
Majority, 87.8%, self-detected a lump in the breast. The
median time from onset of symptoms to diagnosis was 12
months, ranging 3–48.
The commonest histology was invasive ductal carcinoma
,70.7%.
Stage III disease represented 47.58%, while stage I, II and
IV disease made up 7.32%, 19.61% and 25.49% respectively
Hormone receptor (HR) status was unknown in 63.4%,
14.6% were estrogen receptor (ER) only positive, 7.3%
were progesterone receptor (PR) only positive, 4.9% were
ER and PR positive, and 9.8% were ER and PR negative.
Of those who had their HR status checked, 73.2% were HR
positive.
Modified radical mastectomy was the most common
surgical procedure, 46.3%, mastectomy only in 14.6% and
breast conservation in 7.3%. 46.3% of patients
received adjuvant radiotherapy. 48.8% did not receive
adjuvant radiotherapy because they were metastatic,
defaulted or presented late after the surgery. 40.3%
received chemotherapy in adjuvant, neoadjuvant or
metastatic setting.
Hormone receptor positive patients had Tamoxifen.
Median follow up duration was 7 months, ranging 0-64.
Median survival was 13 months and 5 year overall survival
of 2%.
Conclusion
MBC makes up 1.6% of all breast cancer presenting to our
centre, consistent with worldwide findings of about 1%.
Majority presented with locally advanced or metastatic
disease. Outcomes are poor and could be due to late
presentation. Screening programs may translate into
better outcomes.
MBC is frequently hormone receptor positive and may
be more sensitive to hormonal therapy, hence receptor
status testing is recommended.
Low survival and poor follow up made disease free survival
difficult to determine.
EP-1169 Preoperative CT scan in tumor bed
delineation after breast conserving surgery and
oncoplasty
T. Saxena1, V. Goel1, G. Kadyaprath2, D. Arora3, A.K.
Verma 1, P. Agarwal1, P. Kumar1, J. Jain1, R. Shukla1, P.
Kumar 3, A. Masanta3, T.R. Singh4, R. Kaur4, A.K. Anand1
1Max Hospital- Delhi- India, Radiation Oncology, Delhi,
India
2Max Hospital- Delhi- India, Surgical Oncology, Delhi,
India
3Max Hospital- Delhi- India, Medical Physics, Delhi, India
4Max Hospital- Delhi- India, Radiation Therapy
Technologist, Delhi, India
Purpose or Objective
Background: Tumor bed (TB) boost, in addition to whole
breast radiation therapy (WBRT) improves local control
rates as compared to WBRT alone after breast conserving
surgery (BCS). There are several pitfalls in localizing TB
accurately. Surgical clips are generally placed over
pectoralis muscle, even if the tumor is superficial and
hence not truly representative and there is always a
concern of clip migration. Mammogram and MR
mammogram are not quite useful as they are done in a
non-anatomic position. Problem of accurate TB
identification is further compounded in patients with
oncoplastic reconstruction. In oncoplastic surgeries (OPS),
scar is often not representative of tumor location. Seroma
cavity is generally obliterated by tissue repositioning.